AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26439577 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus Reuteri (DSM 17938) (Group B; n = 45)
Number of subjects: 133
Study 26439577 — intervention group
Group type: COMPARATOR
Intervention: Simethicone (Group C; n = 43)
Number of subjects: 133
Study 24386561 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 2mg once daily for 4 weeks
Number of subjects: 10
Study 21649701 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-explanation (n = 18)
Number of subjects: 36
Study 21649701 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 18)
Number of subjects: 36
Study 19659616 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 420
Study 16763075 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher perception of pros concerning smoking cessation
Number of subjects: 554
Study 16763075 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher self‐efficacy perception concerning smoking cessation
Number of subjects: 554
Study 16763075 — intervention group
Group type: COMPARATOR
Intervention: Lower perception of pros of quitting smoking
Number of subjects: 554
Study 15549249 — intervention group
Group type: EXPERIMENTAL
Intervention: Mayo-stem
Number of subjects: 0
Study 15549249 — intervention group
Group type: COMPARATOR
Intervention: Cement-free standard stem
Number of subjects: 0
Study 11770236 — intervention group
Group type: EXPERIMENTAL
Intervention: High Density Diet (HDD) for 7 days followed by routine diet plus HDD for 7 days (Group A)
Number of subjects: 3
Study 11770236 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine diet plus High Density Diet (HDD) for 14 days (Group B)
Number of subjects: 3
Study 11770236 — intervention group
Group type: COMPARATOR
Intervention: Routine diet for 14 days (Group C, control group)
Number of subjects: 3
Study 9304176 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (CTP group, n = 15), 12.5 mg every 8 hours orally, from 24 hours before surgery
Number of subjects: 30
Study 9304176 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON group, n = 15), without captopril
Number of subjects: 30
Study 9304176 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (CTP group)
Number of subjects: 30
Study 9919351 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 160
Study 9919351 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 160
Study 2654068 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 0
Study 2654068 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 2654068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1253193 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg practolol administered orally
Number of subjects: 16
Study 1253193 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg practolol, iv
Number of subjects: 16
Study 1253193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31338880 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimuscarinics
Number of subjects: 507
Study 31338880 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Number of subjects: 507
Study 31338880 — intervention group
Group type: COMPARATOR
Intervention: Bladder diary
Number of subjects: 507
Study 28549264 — intervention group
Group type: EXPERIMENTAL
Intervention: Family group conference (FGC)
Number of subjects: 0
Study 25219686 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic care management (CCM)
Number of subjects: 563
Study 25219686 — intervention group
Group type: COMPARATOR
Intervention: Usual primary care
Number of subjects: 563
Study 22921454 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT), 12 sessions
Number of subjects: 42
Study 22921454 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (healthy subjects), N=42
Number of subjects: 42
Study 21224748 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection of the preseptal orbicularis oculi muscle (group 1)
Number of subjects: 15
Study 21224748 — intervention group
Group type: COMPARATOR
Intervention: Preservation of the orbicularis oculi muscle (group 2)
Number of subjects: 15
Study 19191940 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified positioning and a pillow under their body (Group A)
Number of subjects: 105
Study 19191940 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified positioning (Group B)
Number of subjects: 105
Study 19191940 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 105
Study 19191940 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall bleeding and haematoma formation
Number of subjects: 105
Study 16782644 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative assessment using CT scan
Number of subjects: 24
Study 16782644 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative assessment using navigation system
Number of subjects: 24
Study 15462115 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified omega-3 fatty acids (PFA) at a very low dose (0.85 g EPA and 0.57 g PHA)
Number of subjects: 28
Study 15462115 — intervention group
Group type: COMPARATOR
Intervention: Control group (symptomatic treatment)
Number of subjects: 28
Study 11424542 — intervention group
Group type: EXPERIMENTAL
Intervention: Child and Adolescent Trial for Cardiovascular Health (CATCH) Food Checklist (CFC)
Number of subjects: 365
Study 9241099 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (2‐4 mg daily)
Number of subjects: 24
Study 9241099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8320926 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate or bicarbonate hemodialysis using cuprophane membranes
Number of subjects: 22
Study 8320926 — intervention group
Group type: COMPARATOR
Intervention: HDF or AFB using PAN membranes
Number of subjects: 22
Study 8320926 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate-cuprophane, HDF and AFB-PAN
Number of subjects: 22
Study 3760480 — intervention group
Group type: COMPARATOR
Intervention: Intravenous chemotherapy with Adriamycin, Vincaleucoblastin, Bleomycin, Fluorouracil and Ifosfamid monthly for 10 months
Number of subjects: 20
Study 3760480 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intravenous and intraperitoneal chemotherapy with the same drugs
Number of subjects: 20
Study 31222977 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinol 0.15%
Number of subjects: 40
Study 31222977 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinol 0.3%
Number of subjects: 40
Study 31222977 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 40
Study 29672468 — intervention group
Group type: EXPERIMENTAL
Intervention: Moulage present
Number of subjects: 50
Study 29672468 — intervention group
Group type: COMPARATOR
Intervention: No moulage
Number of subjects: 50
Study 26482056 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors (ChEIs) continuation
Number of subjects: 40
Study 26482056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 24473119 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact (Visible Disability)
Number of subjects: 408
Study 24473119 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact (Invisible Disability)
Number of subjects: 408
Study 24473119 — intervention group
Group type: COMPARATOR
Intervention: Education only
Number of subjects: 408
Study 23197596 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary HPV DNA screening
Number of subjects: 203425
Study 23197596 — intervention group
Group type: COMPARATOR
Intervention: Conventional cytology screening
Number of subjects: 203425
Study 23197596 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV screening (age 25-34)
Number of subjects: 203425
Study 23197596 — intervention group
Group type: COMPARATOR
Intervention: Conventional screening (age 25-34)
Number of subjects: 203425
Study 23197596 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV screening (age 35 and older)
Number of subjects: 203425
Study 23197596 — intervention group
Group type: COMPARATOR
Intervention: Conventional screening (age 35 and older)
Number of subjects: 203425
Study 21033135 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 225
Study 21033135 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 225
Study 18717189 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% stored at 4 degrees C
Number of subjects: 17
Study 18717189 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% stored at 30 degrees C
Number of subjects: 17
Study 18717189 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated eyes)
Number of subjects: 17
Study 15892403 — intervention group
Group type: EXPERIMENTAL
Intervention: suxamethonium (1 mg kg(‐1))
Number of subjects: 376
Study 15892403 — intervention group
Group type: EXPERIMENTAL
Intervention: rocuronium (2 x ED95)
Number of subjects: 376
Study 15892403 — intervention group
Group type: COMPARATOR
Intervention: rocuronium primed with saline, atracurium, cis‐atracurium, vecuronium or mivacurium
Number of subjects: 376
Study 15892403 — intervention group
Group type: EXPERIMENTAL
Intervention: mivacurium
Number of subjects: 376
Study 12590430 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone therapy
Number of subjects: 90
Study 12590430 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital therapy without methadone
Number of subjects: 90
Study 12590430 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic community
Number of subjects: 90
Study 10593465 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EPI) with bolus doses of morphine via an epidural catheter
Number of subjects: 37
Study 10593465 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular analgesia (IA) with 1 mg of morphine applied at the end of the operation and subsequent PCA
Number of subjects: 37
Study 10593465 — intervention group
Group type: COMPARATOR
Intervention: Intravenous analgesia (Control) with PCA only
Number of subjects: 37
Study 8697949 — intervention group
Group type: EXPERIMENTAL
Intervention: Air mattress
Number of subjects: 0
Study 1662880 — intervention group
Group type: EXPERIMENTAL
Intervention: Temafloxacin 600 mg
Number of subjects: 492
Study 1662880 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 750 mg
Number of subjects: 492
Study 7159688 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (50 mg oral dose) from Brand A
Number of subjects: 20
Study 7159688 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (50 mg oral dose) from Brand B
Number of subjects: 20
Study 30813591 — intervention group
Group type: EXPERIMENTAL
Intervention: Tap water supply
Number of subjects: 1369
Study 30813591 — intervention group
Group type: COMPARATOR
Intervention: Alternative water sources (wells, open sources, tankered water)
Number of subjects: 1369
Study 30813591 — intervention group
Group type: EXPERIMENTAL
Intervention: Water consumption
Number of subjects: 1369
Study 27663567 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy
Number of subjects: 162
Study 27663567 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy (control)
Number of subjects: 162
Study 27209480 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid gas permeable (RGP) contact lens wearers
Number of subjects: 23
Study 27209480 — intervention group
Group type: EXPERIMENTAL
Intervention: Keratoconus patients (KC)
Number of subjects: 23
Study 27209480 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 23
Study 24611906 — intervention group
Group type: EXPERIMENTAL
Intervention: Fucoidan (500 mg once daily before breakfast for 3 months)
Number of subjects: 25
Study 24611906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 22440498 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 907
Study 22440498 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 907
Study 22440498 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 907
Study 22440498 — intervention group
Group type: COMPARATOR
Intervention: No abciximab
Number of subjects: 907
Study 19325538 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate breakfast
Number of subjects: 26
Study 19325538 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat breakfast
Number of subjects: 26
Study 19325538 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein breakfast
Number of subjects: 26
Study 17761591 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 460
Study 17761591 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 460
Study 17761591 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin (severe brain injury subgroup)
Number of subjects: 460
Study 17761591 — intervention group
Group type: COMPARATOR
Intervention: Saline (severe brain injury subgroup)
Number of subjects: 460
Study 17761591 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin (GCS scores 9 to 12 subgroup)
Number of subjects: 460
Study 17761591 — intervention group
Group type: COMPARATOR
Intervention: Saline (GCS scores 9 to 12 subgroup)
Number of subjects: 460
Study 15467557 — intervention group
Group type: EXPERIMENTAL
Intervention: McRoberts position
Number of subjects: 27
Study 15467557 — intervention group
Group type: COMPARATOR
Intervention: Lithotomy position
Number of subjects: 27
Study 11409222 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional assist ventilation (PAV) with 9.8 (± 2.1) cm H2O/L and 3.3 (± 1.0) cm H2O/L/sec of volume assist and flow assist
Number of subjects: 8
Study 11409222 — intervention group
Group type: COMPARATOR
Intervention: Control trial (spontaneously breathing without assistance)
Number of subjects: 8
Study 9715712 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex scanning (DD group)
Number of subjects: 179
Study 9715712 — intervention group
Group type: COMPARATOR
Intervention: Clinical examination and ABI measurement (ABI group)
Number of subjects: 179
Study 8790521 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasonography as a primary screening test and colour Doppler imaging as a secondary screening test
Number of subjects: 8678
Study 8790521 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 8678
Study 2532691 — intervention group
Group type: EXPERIMENTAL
Intervention: hANP only
Number of subjects: 20
Study 2532691 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine + hANP
Number of subjects: 20
Study 2532691 — intervention group
Group type: COMPARATOR
Intervention: placebo only
Number of subjects: 20
Study 1233250 — intervention group
Group type: EXPERIMENTAL
Intervention: Strophanthin K (0.125 and 0.25 MG)
Number of subjects: 10
Study 1233250 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanatoside C (0.4, 0.8 and 1.6 mg)
Number of subjects: 10
Study 1233250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31806129 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan
Number of subjects: 1097
Study 28115027 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Feedback (1-minute training with real-time visual feedback)
Number of subjects: 450
Study 28115027 — intervention group
Group type: EXPERIMENTAL
Intervention: Long Feedback (10-minute training with real-time visual feedback)
Number of subjects: 450
Study 28115027 — intervention group
Group type: COMPARATOR
Intervention: No Feedback (NF)
Number of subjects: 450
Study 25406300 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell (BMC) therapy
Number of subjects: 101
Study 23281620 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient training for 6 months
Number of subjects: 74
Study 21242465 — intervention group
Group type: EXPERIMENTAL
Intervention: Contoured foot orthoses
Number of subjects: 20
Study 21242465 — intervention group
Group type: COMPARATOR
Intervention: Flat foot orthoses
Number of subjects: 20
Study 21242465 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot orthoses (both types)
Number of subjects: 20
Study 18290996 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg abacavir
Number of subjects: 600
Study 18290996 — intervention group
Group type: COMPARATOR
Intervention: 200 mg nevirapine
Number of subjects: 600
Study 16404741 — intervention group
Group type: EXPERIMENTAL
Intervention: DVd (pegylated liposomal doxorubicin 40 mg/m², vincristine 1.4 mg/m², dexamethasone 40 mg Days 1-4)
Number of subjects: 192
Study 16404741 — intervention group
Group type: COMPARATOR
Intervention: VAd (conventional doxorubicin 9 mg/m² per day, vincristine 0.4 mg per day, dexamethasone reduced dose)
Number of subjects: 192
Study 16404741 — intervention group
Group type: EXPERIMENTAL
Intervention: DVd
Number of subjects: 192
Study 14744180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 14744180 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (neuroleptics)
Number of subjects: 100
Study 14744180 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Placebo and Active treatment)
Number of subjects: 100
Study 11412157 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine combined with sufentanil 0.75 microg.ml‐1
Number of subjects: 42
Study 11412157 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine alone
Number of subjects: 42
Study 9646213 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg twice daily for four weeks plus amoxicillin 3 g daily during the first and second week (Group A)
Number of subjects: 59
Study 9646213 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg twice daily for 4 weeks plus placebo for two weeks (Group B)
Number of subjects: 59
Study 9646213 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori cured patients
Number of subjects: 59
Study 9646213 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistently Helicobacter pylori positive patients
Number of subjects: 59
Study 9646213 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori-eradicated patients
Number of subjects: 59
Study 8426317 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 mm incisions
Number of subjects: 276
Study 8426317 — intervention group
Group type: COMPARATOR
Intervention: 5.5 mm incisions
Number of subjects: 276
Study 8426317 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 276
Study 2885366 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotiazepam 5 mg
Number of subjects: 8
Study 2885366 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotiazepam 10 mg
Number of subjects: 8
Study 2885366 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotiazepam 20 mg
Number of subjects: 8
Study 2885366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29709099 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg once daily
Number of subjects: 381
Study 29709099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 381
Study 28236563 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension orthosis (Levame)
Number of subjects: 30
Study 28236563 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression orthotic device
Number of subjects: 30
Study 28236563 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 30
Study 26409407 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS stimulation to the primary motor cortex, 20 minutes/day for 5 consecutive days
Number of subjects: 20
Study 26409407 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS stimulation
Number of subjects: 20
Study 23991573 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 165
Study 23991573 — intervention group
Group type: COMPARATOR
Intervention: Blank group (no intervention)
Number of subjects: 165
Study 21918206 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Diabetes Management Program (CDMP)
Number of subjects: 39
Study 21918206 — intervention group
Group type: COMPARATOR
Intervention: Attention Control (AC)
Number of subjects: 39
Study 19065488 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation using the HALO system
Number of subjects: 0
Study 16687979 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretin-X (0.1% cream, 0.025% cream, 0.025% gel, 0.01% gel)
Number of subjects: 1642
Study 16687979 — intervention group
Group type: EXPERIMENTAL
Intervention: Retin-A (0.1% cream, 0.025% cream, 0.025% gel, 0.01% gel)
Number of subjects: 1642
Study 16687979 — intervention group
Group type: COMPARATOR
Intervention: Placebo (drug vehicle)
Number of subjects: 1642
Study 12654603 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/d)
Number of subjects: 70
Study 12654603 — intervention group
Group type: COMPARATOR
Intervention: American Heart Association Step 1 diet alone
Number of subjects: 70
Study 11543414 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (REX) - five sets of leg press exercise to volitional fatigue (6‐10 repetitions) every other day.
Number of subjects: 12
Study 11543414 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 12
Study 8867397 — intervention group
Group type: EXPERIMENTAL
Intervention: Early nutritional support (enteral or parenteral feeding) with appropriate caloric and protein requirement as soon as hemodynamic status was stabilized.
Number of subjects: 38
Study 8867397 — intervention group
Group type: COMPARATOR
Intervention: Conventional method with administration of hypo caloric intravenous regimen and supplement with oral diet as soon as bowel function returned.
Number of subjects: 38
Study 1363640 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil alone (500 mg)
Number of subjects: 12
Study 1363640 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil with food (500 mg)
Number of subjects: 12
Study 6377829 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide (12 micrograms/kg intravenously)
Number of subjects: 6
Study 6377829 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide (5 mg orally)
Number of subjects: 6
Study 6377829 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide (oral administration)
Number of subjects: 6